Clinical Trials Logo

Pseudotumor Cerebri clinical trials

View clinical trials related to Pseudotumor Cerebri.

Filter by:

NCT ID: NCT05308823 Enrolling by invitation - Clinical trials for Idiopathic Intracranial Hypertension

Outcome of Cerebral Venous Sinuses Stenting on Idiopathic Intracranial Hypertension

Start date: March 15, 2022
Phase: N/A
Study type: Interventional

The aim of the work is to asses the positive effect of stenotic sinus segment stenting on idiopathic intracranial hypertension with headache and papilloedema.

NCT ID: NCT05050864 Recruiting - Cerebrospinal Fluid Clinical Trials

Stenting Versus Neurosurgical Treatment of Idiopathic Intracranial Hypertension.

HYDROPTIC
Start date: March 2, 2022
Phase: N/A
Study type: Interventional

Idiopathic intracranial hypertension (HTICi) is a pathology, affecting young adults with a predominance of women, due to an increase in intracranial pressure, which may be associated with stenosis of the cerebral venous sinuses and whose origin remains unknown. This hypertension can lead to papillary edema (OP) which can lead to a narrowing of the visual field and progress to blindness. Along with weight reduction, acetazolamide, which reduces the production of cerebrospinal fluid (CSF), is prescribed as a first-line treatment. Its efficacy is inconsistent in resolving papillary edema and there are many side effects. In the event of ineffectiveness or dependence on acetazolamide associated with hygiene and dietetic rules, a second line of therapy is then considered: neurosurgical (internal shunt of the LCS) or endovascular (venous stenting) treatment. These invasive techniques have each proven their effectiveness in the rapid and permanent resorption of OP, allowing improvement or preservation of visual function. In terms of induced morbidity, the superiority of one technique over the other, if it exists, has not been established. Our objective is to compare the efficacy, safety, and safety of LCS bypass surgery versus venous sinus stenting in HTICi with moderate to severe visual impairment after failure of medical treatment defined by the absence of resorption of the OP after several months

NCT ID: NCT04796935 Completed - Cancer Clinical Trials

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

Start date: April 4, 2021
Phase: N/A
Study type: Interventional

This study will compare the VerTouch device to the conventional palpation technique for performing diagnostic and therapeutic neuraxial procedures.

NCT ID: NCT04603118 Completed - Pseudotumor Cerebri Clinical Trials

Optic Nerve Sheath Diameters in Idiopathic Intracranial Hypertension Patients

Start date: May 1, 2014
Phase: N/A
Study type: Interventional

Idiopathic intracranial hypertensionis a type of increased intracranial pressure. Diagnosis is made by lumbar puncture, which is an invasive technique. The relationship between ICP and optic nerve sheath diameters (ONSD) were examined in our study. Thus, it was investigated whether the optic nerve sheath diameter could be used in the diagnosis of IIH. In the present study, it was found that ONSD measurement by optic USG significantly reflects increased ICP and decreasing pressure via LP is rapidly reflects to ONSD measurement. And it is suggested that ONSD measurements by optic USG, a non-invasive method, can be used in the diagnosis and follow-up of IIH patients.

NCT ID: NCT04314128 Completed - Clinical trials for Idiopathic Intracranial Hypertension

Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Idiopathic Intracranial Hypertension (IIH) is a rare disease, primarily affecting overweight females of child-bearing age. Patients suffer from increased intracranial pressure (ICP), typically resulting in headaches, visual disturbances and bilateral papilledema, pulsatile tinnitus and cognitive deficits. The disease is difficult to diagnose, treat and monitor. The only current method of measuring the ICP in day-to-day clinical practice is by lumbar puncture. This procedure is invasive, and often painful for the patient. There is an unmet need of methods that can reliable measure or estimate ICP in a non-invasive manner. Ultrasound is one such potential method, and the aim of this study is to investigate the use of ocular ultrasound and transcranial doppler to measure or estimate ICP.

NCT ID: NCT04309383 Recruiting - Pseudotumor Cerebri Clinical Trials

ShuntCheck Performance Characteristics in Asymptomatic Pseudotumor Cerebri Patients

Start date: October 29, 2019
Phase:
Study type: Observational

The purpose of the study is to determine if the ShuntCheck test can correctly identify flow or no flow in a ventriculoperitoneal shunt in patients with pseudotumor cerebri.

NCT ID: NCT04207229 Completed - Hydrocephalus Clinical Trials

CERTAS Programmable Valve Registry

CERTAS
Start date: November 21, 2019
Phase:
Study type: Observational [Patient Registry]

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

NCT ID: NCT04115553 Recruiting - Clinical trials for Intracranial Hypertension

Assessment of Venous Drainage in Idiopathic Intracranial Hypertension

HYPERPIC
Start date: February 19, 2020
Phase: N/A
Study type: Interventional

Intracranial hypertension (IIH) is a disorder producing a syndrome of increased intracranial pressure secondary to a compressive intracranial lesion or said to be idiopathic. The most common symptoms are headaches, blindness, pulsatile tinnitus or papillary edema. There are many options for the treatment of IIH, especially neurosurgery (derivation of cerebrospinal fluid or stent placement). Currently, idiopathic IIH has no clear etiology but the hypothesis of sino-venous insufficiency is more and more recognized. The assumption of venous insufficiency has not been demonstrated so far. Therefore the investigators propose to demonstrate that cerebral venous drainage pathways are altered in adult patients with idiopathic intracranial hypertension in comparison to healthy individuals having normal circulation. Assessment will be performed using Magnetic Resonance Imaging which is part of the patient care.

NCT ID: NCT04032379 Recruiting - Clinical trials for Benign Intracranial Hypertension

Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension

Start date: February 14, 2018
Phase:
Study type: Observational [Patient Registry]

Idiopathic intracranial hypertension (IIH) is a condition of unknown etiology, primarily affecting overweight females of childbearing age. Typically, patients experience headache and visual symptoms due to increased intracranial pressure (ICP) and papilledema. The diagnosis is difficult, and outcomes vary from no sequelae to blindness or chronic headaches. No clear prognostic indicators exist. Treatment consists of medication, weight loss, and possibly surgical intervention.There is an unmet need of defining biomarkers with prognostic or diagnostic value and defining predictors of a poor outcome. This project is a prospective, population-based cohort study including clinical data and a biobank (blood samples and cerebrospinal fluid). The investigator's primary aim is to identify biomarkers of diagnostic or prognostic value and to create a clinical IIH database. The clinical database will answer questions about patient characteristics at baseline and during follow-up, identify predictors of outcome, and help create a standardized programme for follow-up and

NCT ID: NCT03963336 Completed - Clinical trials for Idiopathic Intracranial Hypertension

Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension

Start date: July 22, 2017
Phase: Early Phase 1
Study type: Interventional

Idiopathic intracranial hypertension (IIH) is a syndrome characterized by elevated intracranial pressure (ICP) of unknown etiology. The investigators aim to study the quantitative D-dimer level and the role of anticoagulant therapy in the absence of occlusive sinus thrombosis in IIH patients.